# Delonix Bioworks

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delonix-bioworks

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.delonixbio.com
- Total disclosed funding: $14M
- Latest round: Seed (Mar 10, 2021)
- Investors on record: 3

## About

Established in 2021 and based in Shanghai, China. Delonix Bioworks is a biotechnology company that focuses on the development of synthetic biology. In March 2021, new investors Boehringer Ingelheim Venture and IDG Capital co-led USD 14 million in seed funding for Delonix Bioworks. In April 2023, it was awarded Synthetic Biology Start-up to Watch 2023 by EB Insights.

The company is committed to innovative vaccines and engineering bacterial drug development, which provides synthetic vaccines, synthetic cancer therapies, etc. It has developed a synthetic biology platform and a vaccine technology platform. It also develops gene editing techniques and methods for nearly ten pathogenic bacteria, which can assist in the development and upgrading of various whole bacterial and component vaccines.

## Funding rounds

- Seed, Mar 10, 2021, $14M — IDG Capital, Boehringer Ingelheim Venture, ZhenFund

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Seed
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Seed
- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Seed